Thalidomide returns: scandal-hit drug is now used across NHS
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Thalidomide, the cause of the biggest medical scandal of the last century, is today recommended for use across the NHS.
It is the final rehabilitation for a drug that once struck terror into patients when it was prescribed to pregnant women as a treatment for morning sickness in the late 1950s and early 1960s. It turned out to cause birth defects in the foetus and about 10,000 babies were born around the world with stunted arms or legs or, in some cases, no limbs at all.
Thalidomide was withdrawn from sale in 1961 and the scandal led to a review of the marketing, testing and regulating of drugs, culminating in the Medicines Act, 1968.
Now, 50 years later, the National Institute for Clinical Excellence has recommended thalidomide for multiple myeloma, a cancer of the bone marrow. The decision marks a watershed in the drug's slow return to respectability. For years it was shunned, but in the 1990s it was shown to be effective in the treatment of leprosy. Further research suggested the mechanism by which it caused birth deformities, through limiting the blood supply to the foetus's limbs, might be harnessed as a treatment for cancer, by inhibiting the growth of blood vessels that feed tumours.
In Britain, thalidomide has been used to treat brain cancer, kidney cancer and Kaposi's sarcoma, a cancer involving the blood vessels of the skin.
Its most potent effects were shown against multiple myeloma, an incurable disease where the aim of treatment is to alleviate symptoms and minimise side effects.Its precise mechanism of action is unknown but it is thought to inhibit the growth and survival of myeloma cells and has an anti-inflammatory action.
The drug costs £2,100 per treatment cycle and is estimated to be suitable for 2,000 patients with multiple myeloma a year.
Thalidomide is prescribed in Brazil, where there are a large number of leprosy patients, but children are still being born today in South America with limb defects because of ignorance of its effects in pregnancy.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments